Répertoire du corps professoral
Paul Toren
Médecin clinicien enseignant agrégé
paul.toren.1@ulaval.ca
Université Laval
L'Hôtel-Dieu de Québec
9, rue McMahon
Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma
Programme: UpCycle 2.1
Organisme(s) subventionnaire(s): Société de recherche sur le cancer
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 août 2022
au31 juillet 2026
Exploiter les interactions endocriniennes-immunes pour améliorer le traitement des cancers urologiques
Programme: Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2022
au30 juin 2024
Targeting sex steroids to improve the response to bladder cancer immunotherapy
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2021
au30 septembre 2026
Financements des 2 dernières années
A study of macrophages as predictors of prostate cancer radiotherapy response
Organisme(s) subventionnaire(s): Association canadienne d'urologie
Type de financement: Subvention
Établissement tête: Université Laval
Du 26 janvier 2022
au25 janvier 2023
Publications des 5 dernières années
Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin Clinical Genitourinary Cancer, 2024/04. Geneviève Trépanier, Timo Nykopp, Raphaëlla Rosebush-Mercier, Typhaine Gris, Jonathan Fadel, Peter C. Black, Paul Toren. DOI 10.1016/j.clgc.2023.12.004
The sex gap in bladder cancer survival — a missing link in bladder cancer care? Nature Reviews Urology, 2024/03. Paul Toren, Anna Wilkins, Keval Patel, Amy Burley, Typhaine Gris, Roger Kockelbergh, Taha Lodhi, Ananya Choudhury, Richard T. Bryan. DOI 10.1038/s41585-023-00806-2
Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024/02. Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M. DOI 10.5489/cuaj.8341
NS-AUA 2023 Annual Meeting Abstracts - Oncology - Bladder, Renal, Testes. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/10. DOI 10.5489/cuaj.8577
Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial Cancer Medicine, 2023/10. Josée Savard, Hanane Moussa, Jean‐François Pelletier, Pierre Julien, Louis Lacombe, Rabi Tiguert, Yves Caumartin, Thierry Dujardin, Paul Toren, Frédéric Pouliot, Michele Lodde, Yves Fradet, Karine Robitaille, Vincent Fradet. DOI 10.1002/cam4.6598
High infiltration of CD209<sup>+</sup> dendritic cells and CD163<sup>+</sup> macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes. Frontiers in immunology, 2023/06. Molina OE, LaRue H, Simonyan D, Hovington H, Têtu B, Fradet V, Lacombe L, Toren P, Bergeron A, Fradet Y. DOI 10.3389/fimmu.2023.1205266
CUA 2023 Annual Meeting Abstracts - Poster Session 9: Oncology - Prostate (Part 2) Sunday, June 25, 2023 • 7:00-8:30. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/06. DOI 10.5489/cuaj.8417
Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <i>Post Hoc</i> Analysis of the PR.7 Trial 2023/03/31. Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Véronique Turcotte, Patrick Caron, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz. DOI 10.1158/1078-0432.22475735
Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <i>Post Hoc</i> Analysis of the PR.7 Trial 2023/03/31. Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Véronique Turcotte, Patrick Caron, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz. DOI 10.1158/1078-0432.22475735.v1
Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <i>Post Hoc</i> Analysis of the PR.7 Trial 2023/03/31. Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Véronique Turcotte, Patrick Caron, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz. DOI 10.1158/1078-0432.c.6529157
Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <i>Post Hoc</i> Analysis of the PR.7 Trial 2023/03/31. Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Véronique Turcotte, Patrick Caron, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz. DOI 10.1158/1078-0432.c.6529157.v1
Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA). Nutrients, 2023/03. Moussa H, Robitaille K, Pelletier JF, Tourigny R, Fradet Y, Lacombe L, Toren P, Lodde M, Tiguert R, Dujardin T, Caumartin Y, Duchesne T, Julien P, Fradet V. DOI 10.3390/nu15061369
Association des Urologues du Québec Congrès Annuel 2022 - Résumés. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/12. DOI 10.5489/cuaj.8204
Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation. NAR cancer, 2022/11. Lelong EIJ, Khelifi G, Adjibade P, Joncas FH, Grenier St-Sauveur V, Paquette V, Gris T, Zoubeidi A, Audet-Walsh E, Lambert JP, Toren P, Mazroui R, Hussein SMI. DOI 10.1093/narcan/zcac034
Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/10. Turcotte B, Bélanger L, Blais AS, Blouin AC, Bolduc S, Bolduc-Mokhtar A, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Pouliot F. DOI 10.5489/cuaj.7819
Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer. Urologic oncology, 2022/10. Fadel J, Simonyan D, Fradet V, Lodde M, Lacombe L, Fradet Y, Toren P. DOI 10.1016/j.urolonc.2022.09.024
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level. The Journal of urology, 2022/09. Rouleau M, Neveu B, Caron P, Morin F, Toren P, Lacombe L, Turcotte V, Lévesque É, Guillemette C, Pouliot F. DOI 10.1097/ju.0000000000002923
Patients' perceptions on active surveillance for the treatment of small renal masses. Urologic oncology, 2022/08. Charbonneau G, Hudon C, Lavallée LT, Kassouf W, Gaboury I, Toren P, Couture F, Couture F, Foley V, Tétu A, Richard PO. DOI 10.1016/j.urolonc.2022.07.005
Opioid use after uro-oncologic surgeries in time of opioid crisis. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/08. Turcotte B, Jacques E, Tremblay S, Toren P, Caumartin Y, Lodde M. DOI 10.5489/cuaj.7633
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment. European urology open science, 2022/07. Besançon M, Gris T, Joncas FH, Picard V, Bergeron A, Fradet Y, Toren P. DOI 10.1016/j.euros.2022.06.007
Case - Gigantic obstructive calculi in continent urinary diversion. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/07. Fadel J, Akoum N, Lodde M, Toren P. DOI 10.5489/cuaj.7698
CUA 2022 Annual Meeting Abstracts - Poster Session 9: Oncology - Prostate Sunday, June 26, 2022 • 07:30-09:00. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/06. DOI 10.5489/cuaj.7931
CUA 2022 Annual Meeting Abstracts - Poster Session 7: Oncology - Bladder Sunday, June 26, 2022 • 07:30-09:00. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/06. DOI 10.5489/cuaj.7929
Sex steroid modulation of macrophages within the prostate tumor microenvironment. American journal of clinical and experimental urology, 2022/04. Berrehail Z, Boibessot C, Gris T, Joncas FH, Gaignier F, Guillemette C, Lacombe L, Fradet Y, Toren P.
Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy Clinical Nutrition ESPEN, 2022/02. Samuel Fradet, Jean-François Pelletier, Narcisse Singbo, Louis Lacombe, Paul Toren, Michele Lodde, Thierry Dujardin, Rabi Tiguert, Yves Fradet, Karine Robitaille, Vincent Fradet. DOI 10.1016/j.clnesp.2021.12.011
Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and translational medicine, 2022/01. Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P. DOI 10.1002/ctm2.581
Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian journal of andrology, 2022/01. Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P. DOI 10.4103/aja.aja_58_21
Résumés AUQ 2021. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/11. DOI 10.5489/cuaj.7674
Reply by Authors Journal of Urology, 2021/11. Samuel Tremblay, Lily Summers-Trasiewicz, Frédéric Pouliot, Juanita M. Crook, Keyue Ding, Laurence Klotz, Paul Toren. DOI 10.1097/JU.0000000000001946.03
Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer Journal of Urology, 2021/11. Samuel Tremblay, Lily Summers-Trasiewicz, Frédéric Pouliot, Juanita M. Crook, Keyue Ding, Laurence Klotz, Paul Toren. DOI 10.1097/JU.0000000000001946
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/10. Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F. DOI 10.5489/cuaj.7107
Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs. Scientific reports, 2021/09. Boibessot C, Joncas FH, Park A, Berrehail Z, Pelletier JF, Gris T, Bergeron A, Toren P. DOI 10.1038/s41598-021-98903-y
Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer European Urology Focus, 2021/09. Kassim Kourbanhoussen, Catherine McMartin, Michele Lodde, Alexandre Zlotta, Richard T. Bryan, Paul Toren. DOI 10.1016/j.euf.2020.10.002
Northeastern Section of the American Urological Association 73rd Annual Meeting Abstracts. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/09. DOI 10.5489/cuaj.7599
Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival World Journal of Urology, 2021/05/16. Paul Toren, Hervé Brisson, David Simonyan, Hélène Hovington, Louis Lacombe, Alain Bergeron, Yves Fradet. DOI 10.1007/s00345-020-03358-x
Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors. Urologic oncology, 2021/03. Al-Hogbani M, Duguay J, Wagner DC, Haferkamp A, Joubert P, Frees S, Rendon R, Power N, Périgny M, Toren P. DOI 10.1016/j.urolonc.2021.02.014
Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation of long non-coding RNAs 2021/01. Lelong EIJ, Adjibade P, Joncas F, Khelifi G, Grenier VS, Zoubedi A, Lambert J, Toren P, Mazroui R, Hussein SMI. DOI 10.1101/2021.01.05.425492
Images - Para-aortic lymphatic ectasia suggestive of testicular cancer retroperitoneal metastasis. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/01. Chahine S, Toren P. DOI 10.5489/cuaj.6677
Building a Canadian Translational Bladder Cancer Research Network. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/10. Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC, Canadian Bladder Cancer Research Network. DOI 10.5489/cuaj.6887
A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/10. Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Lacombe L, Pouliot F. DOI 10.5489/cuaj.6862
Northeastern Section of the AUA 72nd Annual Meeting Abstracts Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/09.
Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. The Journal of urology, 2020/05. Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Lévesque É, Klotz L, Guillemette C. DOI 10.1097/ju.0000000000000699
EDITORIAL COMMENT. Urology, 2020/04. Toren P. DOI 10.1016/j.urology.2019.11.057
Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? Clinical Genitourinary Cancer, 2019/12. Catherine McMartin, Louis Lacombe, Vincent Fradet, Yves Fradet, Michele Lodde, Paul Toren. DOI 10.1016/j.clgc.2019.07.016
Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients The Prostate, 2019/11. France‐Hélène Joncas, Fabrice Lucien, Mélanie Rouleau, Fannie Morin, Hon Sing Leong, Frédéric Pouliot, Yves Fradet, Caroline Gilbert, Paul Toren. DOI 10.1002/pros.23901
Résumés AUQ 2019. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019/09. DOI 10.5489/cuaj.6229
Images - Sclerosing mesenteritis presenting with unilateral hydro-ureteronephrosis. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019/09. Turcotte B, Toren P, Cloutier J. DOI 10.5489/cuaj.5689
PEG10 is associated with treatment-induced neuroendocrine prostate cancer. Journal of molecular endocrinology, 2019/07. Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A. DOI 10.1530/jme-18-0226
Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis Canadian Urological Association Journal, 2019/05/13. Kaleem S. Atchia, Christopher J.D. Wallis, Neil Fleshner, Paul Toren. DOI 10.5489/cuaj.5996
Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. Urologic oncology, 2019/03. Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M. DOI 10.1016/j.urolonc.2019.01.017
Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine connections, 2019/02. Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F. DOI 10.1530/ec-18-0476
Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. European urology oncology, 2019/01. Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. DOI 10.1016/j.euo.2019.01.009
Les informations contenues dans cette page sont extraites de différents systèmes experts de l’Université Laval. Si vous constatez une erreur ou avez des questions quant aux données affichées, communiquez avec nous en écrivant à l’adresse repertoire-corps-professoral@ulaval.ca. Nous nous assurerons de rediriger votre demande à la bonne personne.